Adjuvant and Salvage Radiotherapy After Prostatectomy for Prostate Cancer: A Literature Review

Pasquier, David; Ballereau, Charles

doi:10.1016/j.ijrobp.2008.07.026

Cited by 51 publications

(28 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Salvage radiotherapy (RT) is often recommended for biochemical relapse after RP (Sidhom et al 2008;Pasquier and Ballereau 2008). Salvage RT targeted to the prostate bed must be administered when the cancer burden is lowest, i.e., when serum PSA is Wrst detectable, because it is highly likely that an increasing PSA reXects local recurrence.…”

Section: Introductionmentioning

confidence: 99%

Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy

Tomita

Kodaira

Furutani

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy

Tomita

Kodaira

Furutani

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15][16] Loeb and colleagues 12 reported impressive long-term undetectable PSA rates on patients with positive surgical margins and/or extracapsular extension and even those with SVI (91% and 75%, respectively). This would suggest SRT is preferable.…”

Section: Evidence From Nonrandomized Seriesmentioning

confidence: 99%

Salvage versus adjuvant radiotherapy after radical prostatectomy: argument for adjuvant radiotherapy

Chin

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Es ist unklar, ob ein PSA-Anstieg oder ein persistierender PSA-Wert nach RT ein Indikator für ein isoliertes Lokalrezidiv, eine disseminierte Metastasierung oder eine Mischform von beidem ist [3,4,21,22,34].…”

Section: Strahlentherapie Bei Persistierendem Psa Oder Anstieg Des Psunclassified

Strahlentherapie des Prostatakarzinoms in der neuen S3-Leitlinie

Martin

Wenz

Böhmer

et al. 2010

Urologe

View full text Add to dashboard Cite

Postoperative adjuvant radiation therapy has achieved special significance based on the results of three randomized studies on stage pT3R1 prostate cancer which provided evidence for prolonged survival in comparison to the "wait and see" strategy. When PSA levels persist or increase after radical prostatectomy, irradiation represents an alternative. In this instance, salvage radiotherapy should be initiated as early as possible, most suitably when the PSA level is <0.5 ng/ml. Side effects of percutaneous radiotherapy using modern techniques are minimal in this stage; severe grade 3 or 4 late sequelae occur in <3% of cases. Low dose rate (LDR) brachytherapy as monotherapy is a primary treatment option for low-risk tumors. In patients with intermediate-risk tumors, data are controversial and cannot be assessed conclusively. LDR brachytherapy should not be administered in high-risk tumors. High dose rate (HDR) brachytherapy combined with percutaneous radiotherapy as an example of a typical dose escalation approach is a primary option for intermediate- and high-risk prostate cancer. Whether additional hormone therapy is needed with HDR brachytherapy is unclear. HDR monotherapy can only be recommended in the clinical trial setting.

show abstract

Adjuvant and Salvage Radiotherapy After Prostatectomy for Prostate Cancer: A Literature Review

Cited by 51 publications

References 65 publications

Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy

Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy

Salvage versus adjuvant radiotherapy after radical prostatectomy: argument for adjuvant radiotherapy

Strahlentherapie des Prostatakarzinoms in der neuen S3-Leitlinie

Contact Info

Product

Resources

About